ArticleNature nanotechnology2019
Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy.
Article in Nature nanotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
196 citing papers in PubMed, 795 citations in OpenAlex.
- Nanotherapeutics for enhanced treatments for ovarian cancer: a comprehensive minireview.Drug delivery · 2026Review
- Surface-displayed cholesterol enhances penetration and anti-tumor activity of a platinum nanodrug by targeting NPC1L1-expressing cancer associated fibroblasts.Nature communications · 2026Article
- A flexibility-driven delivery strategy for cationic liposomes to enhance tumor penetration and promote membrane fusion-mediated cellular entry.Materials today. Bio · 2026Article
- Mucus and tumor penetrating paclitaxel micelles for potent local therapy of cervical cancer.Journal of nanobiotechnology · 2026Article
- Charge-regulated hepatic γ-glutamyltranspeptidase fluorescent probe:Chemical science · 2026Article
- Advances in Camptothecin-Class Compounds Nanomedicines: A Comprehensive Review of Antitumor Strategies.Pharmaceutics · 2026Review
- Article
- Multifunctional nanotherapeutics for targeted modulation of endoplasmic reticulum stress to potentiate cancer therapy.Asian journal of pharmaceutical sciences · 2026Review
- ExperimentalMolecules (Basel, Switzerland) · 2026Article
- Bridging hydrogen-bond-stabilized polymeric coacervate core micelles for high-efficiency drug encapsulation and delivery.Nature communications · 2026Article
- The Role of Biofunctional Polymers in Polymer-Drug Conjugates: From Passive Carriers to Therapeutically Active Platforms.Pharmaceutics · 2026Review
- Permeable nanoreactor eye drop for enzymatic cascade-mediated treatment for acute retinal injury model mimicking geographic atrophy.Nature communications · 2026Article
- Dichotomous role of CD47-SIRPActa pharmaceutica Sinica. B · 2026Article
- Phase-Change Assembling Nanostructures Synergistically Potentiate Tumor Radiosensitivity by Reducing the Stemness of Cancer Stem-Like Cells.Exploration (Beijing, China) · 2026Article
- Prodrug Strategies in Atherosclerosis: Targeted Delivery and Therapeutic Advances.Cardiovascular therapeutics · 2026Review
- Targeted drug delivery systems for pancreatic cancer therapy: advances, challenges, and future perspectives.Frontiers in immunology · 2026Review
- Nanoparticle-Mediated Transcytosis in Tumor Drug Delivery: Mechanisms, Categories, and Novel Applications.Current drug delivery · 2026Review
- Responsive nanomedicine strategies achieve pancreatic cancer precise theranostics.Bioactive materials · 2026Review
- Leveraging engineered mitochondria through intercellular communication network for accelerated transport and delivery.Nature communications · 2025Article
- Transcytotic transportation of size-controlled nanocarriers into dystrophic skeletal muscle leads to therapeutic outcome in mice.Nature communications · 2025Article
136 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A tumour microenvironment imposes barriers to the passive diffusion of molecules, which renders tumour penetration an unresolved obstacle to an effective anticancer drug delivery. Here, we present a γ-glutamyl transpeptidase-responsive camptothecin-polymer conjugate that actively infiltrates throughout the tumour tissue through transcytosis. When the conjugate passes on the luminal endothelial cells of the tumour blood vessels or extravasates into the tumour interstitium, the overexpressed γ-glutamyl transpeptidase on the cell membrane cleaves the γ-glutamyl moieties of the conjugate to generate positively charged primary amines. The resulting cationic conjugate undergoes caveolae-mediated endocytosis and transcytosis, which enables transendothelial and transcellular transport and a relatively uniform distribution throughout the tumour. The conjugate showed a potent antitumour activity in mouse models that led to the eradication of small solid tumours (~100 mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.